These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 23350472)

  • 1. [Anti-Her2 therapy in breast cancer].
    Kuroi K
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():606-13. PubMed ID: 23350472
    [No Abstract]   [Full Text] [Related]  

  • 2. Dual HER2-targeted approaches in HER2-positive breast cancer.
    Ahn ER; Vogel CL
    Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
    Loi S; de Azambuja E; Pugliano L; Sotiriou C; Piccart MJ
    Curr Opin Oncol; 2011 Nov; 23(6):547-58. PubMed ID: 21918439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
    Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
    J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adverse events and supportive therapy of anti-HER2 targeted therapy].
    Kawata Y; Kawaguchi K; Ishiguro H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():240-4. PubMed ID: 25831760
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical pharmacology of targeted drug for breast cancer].
    Ishiguro H; Saji S; Toi M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():443-6. PubMed ID: 23513881
    [No Abstract]   [Full Text] [Related]  

  • 7. [Targeting therapy perspectives].
    Suzuki E; Toi M
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():620-6. PubMed ID: 23350474
    [No Abstract]   [Full Text] [Related]  

  • 8. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India.
    Ghosh J; Gupta S; Desai S; Shet T; Radhakrishnan S; Suryavanshi P; Parmar V; Jalali R; Goyal G; Hawaldar R; Patil A; Nair N; Badwe RA
    Indian J Cancer; 2011; 48(4):391-6. PubMed ID: 22293249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can we optimize treatment of HER2-positive metastatic breast cancer?
    Hamilton EP; Blackwell KL
    Oncology (Williston Park); 2013 Mar; 27(3):180, 182. PubMed ID: 23687786
    [No Abstract]   [Full Text] [Related]  

  • 12. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-directed treatment of metastatic breast cancer: unanswered questions.
    Rao R; Cobleigh M
    Oncology (Williston Park); 2013 Mar; 27(3):176, 178, 180. PubMed ID: 23687785
    [No Abstract]   [Full Text] [Related]  

  • 14. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in novel targeted therapies for HER2-positive breast cancer.
    Murphy CG; Morris PG
    Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous targeting of estrogen receptor and HER2 in breast cancer.
    Azim HA; Piccart MJ
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1255-63. PubMed ID: 20735311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fifteen years of anti-HER2 therapy.
    Davidson NE
    Oncology (Williston Park); 2013 Mar; 27(3):151. PubMed ID: 23687781
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer.
    Aziz H; Marcom PK; Hwang ES
    Ann Surg Oncol; 2015 May; 22(5):1404-5. PubMed ID: 25777094
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of inoperable breast cancer].
    Osaki A; Nakamiya N; Saeki T; Matsuura K
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():581-6. PubMed ID: 23350467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.